Inflammatory Bowel Disease (IBD)REPRO-MICINCT06944873
Metabolic Reprogramming of Monocytes in Inflammatory Flares of Inflammatory Bowel Diseases
An observational study of Inflammatory Bowel Disease (IBD), run by University Hospital, Grenoble at 1 site in France.
Trial summary
Inflammatory bowel diseases, Crohn's disease and haemorrhagic rectocolitis, are pathologies that progress in flare-ups, impacting on patients' quality of life and functional or even vital prognosis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Inflammatory Bowel Disease (IBD)
- What is being tested?
- Blood test 4 EDTA tubes
- How many people
- 30 participants
- Where
- 1 siteFrance
- Study dates
- 1 Jul 2026to 31 Jul 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with IBD in severe relapse requiring hospitalisation for immunosuppressive therapy or endoscopy for relapse.
Who may be able to join
- Men and women over 18
- Managed at the CHUGA for a severe IBD flare-up requiring hospitalisation or endoscopy for flare-up
- Patient not objecting to the REPRO-MICI study
Who cannot join
- Patients protected by law (pregnant or breast-feeding women, minors, patients under guardianship or trusteeship, persons deprived of their liberty or hospitalised under duress).
- Patients with positive HIV, HBV or HCV serology.
- Patients with a positive ELISPOT with no history of treatment for latent tuberculosis.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
Grenoble Alpes University Hospital
La Tronche, 38700
Marianne HUPE, MD PhD, +33446466912, mhupe@chu-grenoble.fr
About this study
Inflammatory bowel diseases, Crohn's disease and haemorrhagic rectocolitis, are pathologies that progress in flare-ups, impacting on patients' quality of life and functional or even vital prognosis. These inflammatory diseases require the use of immunosuppressive and immunomodulatory treatments, the side-effects of which can be significant, and the limited number of which sometimes puts patients and practitioners in a therapeutic impasse from which surgery is the only way out. It is therefore important to be able to develop new therapeutic approaches, ideally better tolerated, that can control inflammation during relapses. Monocytes are one of the main players in the inflammatory reaction. In the laboratory, we have developed a strategy for the metabolic reprogramming of these cells based on the use of oxygen microbubbles to modulate the inflammatory response of monocytes.
- Conditions
- Inflammatory Bowel Disease (IBD)
- Being tested
- Blood test 4 EDTA tubes
- Keywords
- Monocytes, Metabolic reprogramming
- Medical subject headings
- Inflammatory Bowel Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood test 4 EDTA tubesBiological
Blood test 4 EDTA tubes for biological check-up
What is being measured
The primary outcome is the main question the study is designed to answer.
Comparaison of reduction of concentration of inflammatory cytokines and chemokines in cells treated by oxygen microbubbles vs cells not treated
Validation of inhibition of the production of inflammatory cytokines and chemokines by the monocytes treated by oxygen microbubbles
Measured: up to 2 years
Secondary outcomes (2)
Comparaison of tissue factor expression at the membrane of monocytes treated by microbubbles vs monocytes not treated
Inhibition of tissue factor expression at the membrane of treated monocytes
Measured: up to 2 years
Comparaison of glucose metabolism rate in monocytes treated bu microbubbles vs not treated cells
Modulation of glucose metabolism in treated monocytes
Measured: up to 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Apr 2025
- Study start1 Jul 2026 (estimated)
- Primary completion30 Apr 2028 (estimated)
- Study completion31 Jul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Inflammatory Bowel Disease (IBD)Studies of the same condition, open and under way.
- More trials run by University Hospital, GrenobleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Grenoble
- Sponsor type
- University, hospital or other
- Collaborators
- Institute for Advanced Biosciences (IAB), Grenoble
- Responsible party
- Sponsor
- Investigators
- Marianne HUPE, MD PhD, Principal investigator, Grenoble Alpes University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06944873
- Sponsor's protocol ID
- 38RC24.0363
- Acronym
- REPRO-MICI
- Status last verified
- May 2026
- First submitted
- 13 Jan 2025
- Last updated
- 19 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Metabolic Reprogramming of Monocytes in Inflammatory Flares of Inflammatory Bowel Diseases
- ClinicalTrials.gov ID
- NCT06944873
- Acronym / sponsor ID
- REPRO-MICI / 38RC24.0363
- Conditions
- Inflammatory Bowel Disease (IBD)
- Keywords
- Monocytes, Metabolic reprogramming
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- University Hospital, GrenobleUniversity, hospital or other
- Collaborators
- Institute for Advanced Biosciences (IAB), Grenoble
- Study start
- 1 Jul 2026 (estimated)
- Primary completion
- 30 Apr 2028 (estimated)
- Study completion
- 31 Jul 2028 (estimated)
- First posted
- 25 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Inflammatory bowel diseases, Crohn's disease and haemorrhagic rectocolitis, are pathologies that progress in flare-ups, impacting on patients' quality of life and functional or even vital prognosis. These inflammatory diseases require the use of immunosuppressive and immunomodulatory treatments, the side-effects of which can be significant, and the limited number of which sometimes puts patients and practitioners in a therapeutic impasse from which surgery is the only way out. It is therefore important to be able to develop new therapeutic approaches, ideally better tolerated, that can control inflammation during relapses. Monocytes are one of the main players in the inflammatory reaction. In the laboratory, we have developed a strategy for the metabolic reprogramming of these cells based on the use of oxygen microbubbles to modulate the inflammatory response of monocytes.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with IBD in severe relapse requiring hospitalisation for immunosuppressive therapy or endoscopy for relapse.
Key inclusion criteria (3 listed)
- Men and women over 18
- Managed at the CHUGA for a severe IBD flare-up requiring hospitalisation or endoscopy for flare-up
- Patient not objecting to the REPRO-MICI study
Key exclusion criteria (3 listed)
- Patients protected by law (pregnant or breast-feeding women, minors, patients under guardianship or trusteeship, persons deprived of their liberty or hospitalised under duress).
- Patients with positive HIV, HBV or HCV serology.
- Patients with a positive ELISPOT with no history of treatment for latent tuberculosis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood test 4 EDTA tubesBlood test 4 EDTA tubes for biological check-up | Biological | – |
Primary outcome
Comparaison of reduction of concentration of inflammatory cytokines and chemokines in cells treated by oxygen microbubbles vs cells not treated
Time frame: up to 2 years
Validation of inhibition of the production of inflammatory cytokines and chemokines by the monocytes treated by oxygen microbubbles
2 secondary outcomes
Comparaison of tissue factor expression at the membrane of monocytes treated by microbubbles vs monocytes not treated
Time frame: up to 2 years
Comparaison of glucose metabolism rate in monocytes treated bu microbubbles vs not treated cells
Time frame: up to 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 May 2026.
- Individual participant dataSharing planned: No
Related trials for Inflammatory Bowel Disease (IBD)
Not yet recruitingPhase 1
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Ulcerative Colitis, Crohn's Disease
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
Recruiting
Effect of Mediterranean Diet in Inflammatory Bowel Disease
Inflammatory Bowel Disease
RecruitingObservational study
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Crohn Disease (CD), Colitis Ulcerative
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Marianne HUPE, MD PhD principal investigator
Grenoble Alpes University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Inflammatory Bowel Disease (IBD), run by University Hospital, Grenoble at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 19 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Marianne HUPE, MD PhD (+33446466912, mhupe@chu-grenoble.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Comparaison of reduction of concentration of inflammatory cytokines and chemokines in cells treated by oxygen microbubbles vs cells not treated (time frame: up to 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2026; AzTrials last refreshed its copy on 8 Nov 2026.